Despite intensive research and clinical trials, amyotrophic lateral sclerosis (ALS) remains a progressive disease with a fatal outcome. One of the key obstacles in finding a treatment for ALS is the lack of sufficiently sensitive measures to evaluate potential drugs or treatments in clinical trials. A useful and reproducible follow-up method may facilitate assessment of treatments aimed at reducing or preventing motor neurone degeneration as seen in ALS.
Several motor unit number estimation (MUNE) methods have been developed in an attempt to follow the progression of ALS, and have been shown to be a more sensitive tool of disease progression than clinical measures. 1, 2 These methods have limitations, including subjectivity, time required, or complexity of performance or analysis.
For these reasons, a new MUNE method was recently developed, MScanFit MUNE (MScan). 3 This method records a detailed stimulus-response curve, or "compound muscle action potential (CMAP) scan," 4 and then fits a model that comprises the thresholds, threshold variability, and amplitudes of all the motor units contributing to the CMAP. The MScanFit program takes full account of the probabilistic nature of motor unit firing, and also incorporates an allowance for the neuromuscular instability that may occur in ALS. The method is simple, quick, and easy to use and has shown promising results on simulated data 3 and in a few clinical studies. [5] [6] [7] [8] In our first clinical study, we compared the reproducibility in patients with ALS and in healthy subjects of MScan with 2 other well-established MUNE methods, multiple-point stimulation (MPS) and motor unit number index (MUNIX). 5 The results show that MScan was significantly more reproducible than MPS or MUNIX. Moreover, MScan had the ability to differentiate ALS patients from healthy controls at an earlier stage of the disease than MPS or MUNIX. In another recent study, we found that MScan was more sensitive for revealing abnormalities in ALS than quantitative motor unit potential analysis parameters. 8 These results suggest the potential utility of MScan in the clinic and in research studies, where the ability to detect motor unit loss may be helpful in ALS and other neuromuscular disorders. The potential of MScan for longitudinal studies remains unanswered. Therefore, the aim of this study was to evaluate the potential of MScan as a measure of disease progression in ALS and progressive muscular atrophy (PMA) when compared with MPS and MUNIX, the ALS Functional Rating Scale-Revised (ALSFRS-R), and CMAP amplitude.
METHODS
Subjects. Twenty-seven patients with ALS or PMA were included in this study between December 2015 and February 2017. For purposes of simplicity, all patients will be referred to in the study as having ALS. All patients enrolled in our study had undergone an exclusionary work-up for ALS mimics before entry, for confirmation of diagnosis, including blood and cerebrospinal fluid tests, magnetic resonance imaging, and electromyographic (EMG) studies. Twenty-three patients completed 4-month follow-up examinations and 16 completed 8-month follow-up examinations. FIGURE 1 shows a schematic flowchart of the patient inclusion and follow-up. Drop-out from the study was either due to death, severe physical weakness, or mental health reasons. Patients were categorized according to the revised El Escorial criteria. 9 At baseline, 5 of the patients were categorized as definite, 5 as probable, 12 as probable laboratory-supported, and 1 as possible ALS. Four had only lower motor neuron signs and were categorized as PMA. Patients were recruited from the Departments of Neurology and Neurophysiology at Aarhus University Hospital. All participants signed informed consent. The project was approved by the regional scientific ethics committee and the Danish Data Protection Agency. Exclusion criteria were carpal tunnel syndrome, polyneuropathy, or conditions that could cause polyneuropathy.
Clinical Examinations. All patients underwent a detailed neurological examination during which deep tendon reflexes were tested. The ALSFRS-R was used to score the patients' functional ability. 10 Electrophysiological Examinations. All patients underwent routine motor and sensory nerve conduction studies and 3 MUNE assessments (MPS, MUNIX, and MScan) at baseline, 4 months, and 8 months. Recordings were made on the thenar muscles on the least affected side. Each subject's hand was cleansed with skin prepping gel and alcohol. A warming lamp kept the skin temperature between 32 and 36 C. The active electrode was placed over the abductor pollicis brevis (APB) muscle and the reference electrode was placed on the interphalangeal joint of the thumb. A ground electrode was placed on the dorsum of the hand. All electrophysiological examinations, except for MScan, were done using a Keypoint EMG machine version 2.11 (Dantec, Skovlunde, Denmark). Most of the measurements were done by the same examiner (A.B.J.), who remained blinded to the previous recordings. Final calculations of MUNE values were made after all the data had been collected, and were done by the same examiner who had performed the recordings. The 3 MUNE methods were performed in accordance with earlier protocols 5 in the following order: (1) MPS; (2) MUNIX; and (3) MScan. The examiner had equal experience with MScan, MUNIX, and MPS.
MPS MUNE. Supramaximal percutaneous stimulation was delivered to the wrist by a hand-held bipolar stimulator to record the median nerve CMAP. The CMAP amplitude was measured from baseline to negative peak. A surface-recorded motor unit potential (SMUP) with a minimum amplitude of ≥25 μV was measured as an all-or-none response by gradually increasing the stimulus intensity. Next, the stimulator was moved to a new site along the median nerve and the procedure was repeated until 10 SMUPs had been recorded with different amplitudes, sizes, and shapes. [11] [12] [13] In patients with less than 10 SMUPs, we recorded as many as possible. The MUNE value was calculated by dividing the CMAP amplitude by the average amplitude of the recorded SMUPs.
Motor Unit Number Index. A supramaximal CMAP was measured again with the same recording electrodes kept at the same position. Next, the patient was asked to perform an abduction of the thumb while the examiner provided manual resistance. Ten contractions were performed with increasing isometric force and 10 EMG surface interference patterns (SIP) were recorded at a minimum of 20 mV/ms. There was a break of 30 seconds between each recording to avoid fatigue. The data from the recordings were processed in an Excel file to obtain MUNIX values. MUNIX uses a mathematical calculation based on the CMAP and SIP to estimate the motor unit number. 13 MScanFit MUNE. The new MUNE method, MScan, was recently developed as part of the Qtrac software. 3 The TRONDNF recording protocol was used for the recordings. After recording a maximal CMAP by stimulating the median nerve at the wrist, the stimulus was gradually reduced from supramaximal level to subthreshold in 0.2% steps to generate a detailed and inverted stimulus-response curve or CMAP scan. 4 The stimulus-response curve describes the amplitude of the motor response as a function of stimulus current, due to recruitment of more and more motor units with increasing stimulus intensity. In MScan, a model is fitted to the recorded stimulus-response curve (scan) to obtain an estimate of motor unit number and the distribution of motor unit sizes and thresholds. The model in the Qtrac program consists of N motor units, each defined by 3 parameters: size; threshold; and relative spread of threshold, defined as the coefficient of variation of the threshold and expressed as a percent (100 × [standard deviation of threshold] / threshold). The number of motor units was estimated offline automatically, using the MScanFit component of the QtracP analysis program.
Statistics. MUNE values ranged from 1 to 251 and were positively skewed. Because we were interested in percent changes rather than absolute changes, the MUNE values were normalized by log transformation before making paired comparisons. Log transformation was not considered appropriate for the ALSFRS-R and CMAP values, which were negatively skewed. Following Shefner et al.,
14 the 6 patients with average MUNE values of less than 10 at baseline were excluded from the assessments of decline in MUNE values, as these values were excessively sensitive to small changes, and for MPS MUNE and MUNIX inappropriately registered an increase from baseline to 4 months. Changes from baseline to 4 and 8 months were assessed by paired t-tests. Within-subject changes from baseline to 4 months and from 4 to 8 months were also combined to estimate a mean percent change per month, on the assumption that the decline in motor unit numbers with time is exponential. 15 Correlation analyses between the MUNE methods and ALSFRS-R were done with the Spearman rank correlation. P < 0.05 was considered significant. All analyses were done with QtracP software. * One did not fulfill the diagnosis of amyotrophic lateral sclerosis (ALS) or progressive muscular atrophy (PMA), and 2 had atrophy of the abductor pollicis brevis muscle that was too severe to permit performance of MUNE.
** Severe physical weakness or mental health reasons.
*** Death (3 patients) or severe physical weakness or mental health reasons (4 patients).
RESULTS
Patients' demographics are summarized in Table 1 . Among the patients, 18 (67%) were newly diagnosed, whereas 9 (33%) were included in the study relatively late after time of diagnosis. FIGURE 2 shows the absolute values for MScan, MPS, MUNIX, ALSFRS-R, and CMAP between baseline and 4 and 8 months for each patient. As depicted in the figure, the baseline values are spread widely, indicating that patients were at different stages of the disease at the baseline recordings. Moreover, it is also noticeable that the change of values varied from patient to patient; that is, some of the patients were fast progressers, with a steep decline, and some are slow progressers, with a less steep decline or even a small incline. Table 2 shows the geometric mean values of MPS, MScan, MUNIX, and the mean values of CMAP amplitude and ALSFRS-R at baseline and after 4 and 8 months. FIGURE 3 shows the declines in MUNE and other measures over 4 and 8 months.
When evaluating each of the methods' ability to detect a change during follow-up (Table 2) , we found that only ALSFRS-R and MScan registered significant changes, and MScan registered the steepest average decline of 8.7% per month. MPS, MUNIX, and CMAP amplitude did not change significantly at any time-point.
The greater decline of MUNE values compared with CMAPs (Table 2) implies that SMUP amplitudes increased slightly. Thus, the mean SMUP amplitude estimated by MScan increased by 47 AE 17 μV over 4 months and by 68 AE 27 μV over 8 months (P = 0.011, n = 19, and P = 0.026, n = 14, respectively). For MPS and MUNIX, the corresponding SMUP amplitude increases were not significant: MPS, 0 AE 18 μV and 13 AE 47 μV (P = 0.92, n = 19, and P = 0.77, n = 14); and MUNIX, 15 AE 11 μV and 39 AE 27 μV (P = 0.21, n = 18, and P = 0.17, n = 13).
Correlations between the 5 measured variables are listed in Table 3 . Table 3 (part a) shows strong correlations between the 3 MUNE measurements, especially between MScan and MPS. 4 MScan and MPS also correlated better than MUNIX with ALSFRS-R. Table 3 (parts b and c) shows that correlations between the MUNE changes over 4 and 8 months were weaker, but still statistically significant. On the other hand, changes in ALSFRS-R were not significantly related to any of the MUNE changes.
DISCUSSION
This study has demonstrated the follow-up potential of a new promising MUNE method, MScan, compared with 2 other MUNE methods, MPS and MUNIX, and with CMAP and the clinical measure ALSFRS-R. Only MScan and ALSFRS-R registered a significant progression of ALS. MScan measured the steepest decline between baseline and 4 and 8 months, respectively. The results provide evidence for the potential of MScan as a tool in detecting motor unit loss over time in ALS.
MUNE methods have long been of interest in research. They have been shown to be more sensitive in measuring disease progression in ALS than clinical measures and ALSFRS-R, 1,2,16,17 and may predict survival of ALS patients better than measures of strength or function. 18 Previous studies with ALS patients showed that incremental stimulation MUNE showed a significantly larger decline than CMAP, ALRFRS-R, and upper motor neuron measurements. 14, 19 A larger decline in MUNE values than CMAP can be explained by collateral reinnervation, and we can presume that this also explains the significant increase in mean SMUP amplitude that we found by MScan. In a study with 17 ALS patients, high-density MUNE and MUNIX decreased significantly more over a period of 8 months compared with manual muscle testing, ALSFRS-R, and CMAP. 20 In a similar study, however, the decline of MUNIX was similar to ALSFRS-R, and CMAP. 21 In yet another study, high-density MUNE was sensitive to motor neuron loss early in the disease course when compared with other clinical measures. 22 MUNE remains a research tool rather than a routine tool used in the clinic. Some of the reasons for this are its various limitations, such as subjectivity or the difficulty or length of time for performing or analyzing the recordings. A recent study, however, showed that the new MUNE method, MScan, takes into account most of the limitations that have been found in other MUNE methods. It was shown to have excellent reproducibility in both inter-and intrarater measurements and was simple and quick to perform and analyze. Also, MScan had the ability to differentiate ALS patients from healthy controls in an earlier stage of the disease when compared with MPS or MUNIX. 5 In contrast to the aforementioned studies, we did not find any significant decline in CMAP amplitude or in the 2 traditional MUNE methods, MPS and MUNIX, over 8 months. An explanation for this could be that some patients were included relatively late after the onset of symptoms. This means that, at Data expressed as mean AE standard deviation; n = number of patients.
baseline, some patients had progressed quite far in their disease process and had severe atrophy of hand muscles. Most patients with slow progression underwent all of the follow-up examinations, whereas patients with fast progression were more likely to drop-out. However, MScan was able to detect significant disease progression at both 4 and 8 months of follow-up. This suggests that MScan is a more sensitive tool than the 2 traditional MUNE methods for measuring motor unit loss over time in patients with ALS. The small number of patients is a limitation in this study but is comparable with other similar studies, and the number of drop-outs is in line with that expected in this fatal disorder. The small number of patients did not allow us to do analyses for subgroups of patients with differing disease onset (bulbar vs. limb) or category (PMA vs. ALS). The progression rate was different in these subgroups, which may be expected to influence the sensitivity of MUNE methods. A limitation of MScan is that the recording method described here used specialized Qtrac software and nerve excitability testing equipment. However, a freeware program is available that can be applied to CMAP scans generated with any EMG machine. 3 The mean percent decline in MUNE per month found for MScan in this study (8.7% ) is comparable with the highest rates of decline previously reported for other MUNE methods, 8.94% for MPS 14 and 8.1% for MUNIX and high-density surface MUNE, 20 reported as a 49.1% decline over 8 months. Other MUNE studies have reported more modest rates of decline, 3.2%-3.7% and 5%-5.6% for MUNIX, 17, 23 or 2.35% for MPS, 24 which are closer to those we found for MPS (3.4%) and MUNIX (4.8%). All studies reported a slower rate of decline for ALSFRS-R, similar to our value of 1.9% per month-namely 2.3%, 17 3.5%, 23 and 1.07%. 24 We found strong correlations between the 3 MUNE measurements, especially between MScan and MPS, as seen our previous study. 4 However, a significant decline was found only for MScan. One explanation for this discrepancy may be that the other methods were more affected by recording from other muscles in patients with severe hand muscle atrophy. Although the percent changes in MPS and MUNIX over 8 months were not statistically significant, they correlated well with the changes in MScan (Table 3 , part c), yet not with ALSFRS-R. This may reflect the fact that the MUNE measurements were all restricted to the thenar muscle, whereas ALSFRS-R is a global measure, not based on a single muscle. ALSFRS-R may be influenced by its self-reported nature. 25 This can be influenced by many factors, such as day-today variations in a patient's symptoms, the patient's memory, and the manner in which the questions are asked, which can be impacted inadvertently by the clinician. Some patients lose the ability to speak and are dependent on nonverbal methods to communicate and answer questions, which can also lead to errors. Another factor that may explain the lack of correlation between ALSFRS-R and MUNE values may be the tendency for ulnar-mediated thenar muscle fibers to be recruited in atrophic muscles, and this could also account for some of the increases in CMAP amplitude and MUNE with time (FIG. 2) . To avoid this possibility, it would seem desirable in future studies to perform recordings in an additional muscle, such as tibialis anterior 26 or multiple muscles, 17 rather than only APB. For MUNE correlations with CMAP amplitude, the amplitude obtained during the particular MUNE recording is used.
*Statistically significant correlation (P < 0.05).
In conclusion, in this study we found that MScan was the most sensitive of the 3 MUNE methods for detecting disease progression in ALS. MScan is a reproducible and sensitive method that is quick and easy to perform, and serves as a more objective measure than ALSFRS-R. MScan therefore appears to be a useful follow-up method for assessing the effects of therapeutic agents for ALS in future drug trials.
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